You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR LESTAURTINIB

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Lestaurtinib

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00079482 ↗	Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)	Completed	Cephalon	Phase 2	The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).
NCT00084422 ↗	N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 1	RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
NCT00084422 ↗	N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	Completed	New Approaches to Neuroblastoma Therapy Consortium	Phase 1	RATIONALE: CEP-701 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of CEP-701 in treating young patients with recurrent or refractory high-risk neuroblastoma.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Lestaurtinib

Condition Name

Chart
Table

Condition Name for
Intervention	Trials
Leukemia	2
Myelofibrosis	2
Polycythemia Vera	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for
Intervention	Trials
Leukemia, Myeloid, Acute	3
Leukemia	3
Polycythemia	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Lestaurtinib

Trials by Country

Map
Table

Trials by Country for
Location	Trials
United States	108
Canada	11
Australia	6
New Zealand	2
Germany	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for
Location	Trials
Pennsylvania	6
New York	6
Maryland	5
California	5
Texas	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Lestaurtinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	3
Phase 1/Phase 2	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	5
Active, not recruiting	2
Unknown status	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lestaurtinib

Sponsor Name

Chart
Table

Sponsor Name for
Sponsor	Trials
National Cancer Institute (NCI)	4
Cephalon	3
Children's Oncology Group	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for
Sponsor	Trials
Other	7
NIH	4
Industry	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.